Breast Cancer | Oncology Today with Dr Neil Love: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer (Companion Faculty Lecture)

Featuring a slide presentation and related discussion from Dr Tiffany A Traina, including the following topics:

• Extended follow-up with pembrolizumab/chemotherapy for patients with previously untreated PD-L1-positive metastatic triple-negative breast cancer (mTNBC) (0:00)
• ASCENT trial: Survival advantage with sacituzumab govitecan versus physician's choice of chemotherapy for patients with relapsed/refractory TNBC (2:49)
• Treatment-associated side effects with sacituzumab govitecan (5:32)
• Activity of sacituzumab govitecan irrespective of TROP2 expression level and in patients with brain metastases (6:48)
• Ongoing Phase III studies evaluating sacituzumab govitecan in earlier lines of treatment (eg, ASCENT-03, ASCENT-04) (8:51)
• Efficacy and tolerability of trastuzumab deruxtecan in patients with HER2-low and HER2-ultralow metastatic breast cancer (10:26)
• Activity and ongoing investigations of other novel agents and strategies for mTNBC (20:05)

CME information and select publications